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Background and Objective: Progressive loss of lung function is a major cause of
morbidity in CF patients; more rapid declines are associated with earlier mortality.
Ivacaftor improves lung function in CF patients with a G551D mutation, but whether
treatment affects FEV1 rate of decline is unknown. Our goal is to examine whether
ivacaftor therapy alters the rate of lung function decline in CF patients with a
G551D mutation compared with CF patients who have F508del mutations.
Methods: A propensity score will be used to match CF patients with a G551D
mutation who received ivacaftor in clinical trials for up to 144 weeks (n = 192) in
a 1:5 ratio with patients in the U.S. Cystic Fibrosis Foundation Patient Registry
homozygous for the F508del mutation. Matching will be based on measures such
as age, gender, % predicted FEV1, and P. aeruginosa infection. Inclusion criteria
for controls will be F508del homozygous genotype, age 6 years, sweat chloride
>40mmol/L, no evidence of lung transplant, and clinical stability based on care
episode, medication, and spirometry data. The annual rate of change in % predicted
FEV1 by group will be estimated for up to 3 years and the difference in rate of
change between groups will be assessed (mixed effects model).
Results: Preliminary results showed that the annualized rate of decline in %
predicted FEV1 in ivacaftor-treated patients is 0.60 percentage points (95%CI:
−1.12, −0.08). The rate of decline in the F508del population will be available at
the time of this presentation.
Conclusions: This analysis is expected to determine whether ivacaftor therapy alters
the rate of decline in FEV1 for CF patients with the G551D mutation.
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Objectives: To evaluate the effect of short-term (4 weeks) and long-term (48 weeks)
ivacaftor treatment on hyperpolarized helium-3 magnetic resonance imaging
(3He-MRI)-deﬁned ventilation defects in patients with cystic ﬁbrosis (CF) and a
G551D-CFTR mutation on at least 1 allele.
Methods: This was a single-center, 2-part, Phase 2 study of CF patients who had a
G551D-CFTR mutation and % predicted FEV1 40%. Part A was a single-blind,
placebo-controlled study comprising 4 weeks of ivacaftor treatment and Part B was
an open-label, 48-week study (washout between A and B 4 weeks). Outcome
measures were the mean change from baseline in total ventilation defect (TVD, the
proportion of total ventilation defect volume to total lung volume) and total defect
volume (TDV) at 4 weeks (Part A) and through 48 weeks (Part B), as measured by
3He-MRI.
Results: In Part A (n = 8, mean age 18.9 years), 3He-MRI revealed that ivacaftor
treatment reduced the TVD by a mean of 8.2 percentage points (P = 0.0547) and the
mean TDV by 0.48 L (P = 0.0313). In Part B (n = 9, mean age 24.4 years), through
48 weeks the mean decrease in TVD was 6.3 percentage points (P = 0.1953) and the
mean decrease in TDV was 0.31 L (P = 0.2656). These results were associated with
a 12.8-point increase (P = 0.0078) in mean % predicted FEV1 in Part A (4 weeks)
and a 5.2-point increase in Part B (P = 0.1953).
Conclusions: Total ventilation defect volume in patients with CF and the G551D-
CFTR mutation was responsive to ivacaftor therapy. 3He-MRI may be useful for
assessing ventilation defects that may not be captured using traditional spirometry,
such as location of defects or disease burden.
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Objectives: In the current study, we examined relationships between pulmonary
bloodﬂow (PBF) and FEV1 in CF patients with mild vs moderate and severe disease.
Methods: 16 patients with CF were prospectively evaluated. 8 patients were
included in the mild CF lung disease group (FEV1 >80% predicted, mean FEV1% =
103.6±10.4; mean age = 14.8±2 yrs, 6 males, 2 females) and 8 were included
in the moderate-severe CF lung disease group (FEV1 <80% predicted, mean
FEV1% = 56.6±11.6; mean age = 18.0±0.8 yrs, 3 males, 5 females). 17 non-CF,
normal subjects served as controls (mean age = 18.6±6.9 yrs; 7 males, 10 females).
Aorto-pulmonary collateral blood ﬂow (APCBF) was calculated for each subject.
The relationship between APCBF and FEV1% was modeled using nonparametric
regression. Group differences were assessed by ANOVA.
Results: APCBF was similar to that of non-CF controls for CF patients with
FEV1 >100%. APCBF increased as FEV1% in CF subjects fell below 101.5%,
with high APCBF seen in moderate-severe lung disease compared to controls (0.89
vs. 0.20 L/min, (p< 0.0001). APCBF correlated negatively with FEV1% (R2 = 0.55,
p = 0.039).
Conclusion: APCBF was within the normal range in CF subjects with mild lung
disease but rapidly increased as FEV1% dropped below 100%. A signiﬁcant increase
in the APCBF compared to controls was measured in patients with moderate-severe
CF lung disease. APCBF may serve as a novel biomarker of early CF pulmonary
disease.
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Objectives:We examined changes in sputum Pseudomonas aeruginosa (Pa) density
(log10CFU/g) and FEV1% predicted among patients (pts) enrolled in a 24 wk
randomized comparison of APT-1026 (levoﬂoxacin nebuliser solution; LNS) and
tobramycin nebuliser solution (TNS) to determine if there was a relationship
between change in bacterial density and FEV1 (NCT01270347).
Methods: Bivariate linear regressions for FEV1% predicted change as a function
of sputum Pa density change were performed at the ends of each of four 28-day
study windows (wks 0−4, 4−8, 16−20, 20−24) in pts who had received no antibiotic
(ABX) treatments other than one of the study drugs. Relationships between sputum
Pa density change and FEV1 change were analyzed using repeated measures models
with effects/covariates for treatment, visit, baseline sputum Pa density, interaction
terms, and relevant baseline characteristics.
Results: 207 pts (143 treated with LNS; 64 with TNS) had data for at least two
consecutive visits (i.e. one window); 154 had 2 windows, 85 had 3 windows,
and 68 had 4 windows. No signiﬁcant correlations were observed between 28-day
Pa sputum density change and FEV1 change in any study window (P values range:
0.3−0.6; R2: 0.0015–0.0159) or by treatment group. Repeated measures results were
consistent with bivariate regression.
Conclusion: Inhaled ABX presumably provide an FEV1 beneﬁt via antimicrobial
activity. However, individual FEV1 changes in pts receiving (or being withdrawn
from) inhaled ABX for 28 days do not correlate linearly with changes in Pa density
from expectorated sputum, suggesting that sputum Pa density changes inadequately
reﬂect inhaled ABX activity in the CF airway.
